Search
Atogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigationalto other preventative therapies. … It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.
Categories: Calcitonin Gene-Related Peptide Receptor Antagonists1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))
go.drugbank.com/drugs/DB11331ApprovedWithdrawnThe product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.
Abatacept
go.drugbank.com/drugs/DB01281ApprovedInvestigationalAbatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human … The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes.
Categories: Selective T Cell Costimulation ModulatorAcetohexamide
go.drugbank.com/drugs/DB00414ApprovedWithdrawnA sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma … [A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients
Products: TEXATE-T, NORDIMET 10MG ILO I E FEREszopiclone
go.drugbank.com/drugs/DB00402ApprovedInvestigationalIt is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_. … Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia.
Ertugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. … [A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621]
Pegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigationalIt is used following surgical resection of the primary tumor to detect areas of remaining cancer. … [L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547]
Insulin glulisine
go.drugbank.com/drugs/DB01309Approvedto produce or synthesize the insulin needed to manage circulating blood sugar levels. … Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent … classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.